Showing results (11-20 of 394) with videos related to
Sort By:
Pageof 40
Biochemical and Biophysical Research Communications|October 15, 1993
Nitric oxide-releasing agents enhance cytokine-induced tumor necrosis factor synthesis in human mononuclear cellsA Eigler, B Sinha, S EndresJournal of Immunology (Baltimore, Md. : 1950)|April 15, 1995
Exogenous and endogenous nitric oxide attenuates tumor necrosis factor synthesis in the murine macrophage cell line RAW 264.7A Eigler, J Moeller, S EndresThe Journal of Infectious Diseases|March 14, 1998
In vivo synthesis of tumor necrosis factor-alpha in healthy humans after live yellow fever vaccinationU T Hacker, T Jelinek, S Erhardt, et al.The Journal of Pharmacology and Experimental Therapeutics|December 22, 1999
Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in miceG Hartmann, C Bidlingmaier, B Siegmund, et al.Journal of Molecular Medicine (Berlin, Germany)|August 4, 2001
Shock waves: a novel method for cytoplasmic delivery of antisense oligonucleotidesK Tschoep, G Hartmann, R Jox, et al.American Journal of Physiology. Regulatory, Integrative and Comparative Physiology|September 15, 2001
Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha productionB Siegmund, G Fantuzzi, F Rieder, et al.European Journal of Immunology|January 1, 1995
Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoidsB Sinha, J Semmler, T Eisenhut, et al.Immunological Investigations|May 16, 2006
Sphingosine kinase and sphingosine-1-phosphate regulate migration, endocytosis and apoptosis of dendritic cellsS Eigenbrod, R Derwand, V Jakl, et al.International Journal of Immunopharmacology|July 1, 1995
The specific type IV phosphodiesterase inhibitor rolipram differentially regulates the proinflammatory mediators TNF-alpha and nitric oxideT F Greten, A Eigler, B Sinha, et al.European Journal of Pharmacology|March 28, 1996
Cicaprost and the type IV phosphodiesterase inhibitor, rolipram, synergize in suppression of tumor necrosis factor-alpha synthesisT F Greten, B Sinha, C Haslberger, et al.Pageof 40